Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Melina Peressini, Rosario Garcia-Campelo, Bartomeu Massuti, Cristina Marti, Manuel Cobo, Vanesa Gutiérrez, Manuel Dómine, Jose Fuentes, Margarita Majem, Javier de Castro, Juan Felipe Cordoba, Maria Pilar Diz, Dolores Isla, Emilio Esteban, Enric Carcereny, Laia Vila, Alberto Moreno-Vega, Silverio Ros, Amaia Moreno, Francisco Javier Garcia, Gerardo Huidobro, Carlos Aguado, Victor Cebey-Lopez, Javier Valdivia, Ramon Palmero, Pilar Lianes, Marta Lopez-Brea, Oscar Juan Vidal, Mariano Provencio, Edurne Arriola, Javier Baena, Mercedes Herrera, Helena Bote, Magdalena Molero, Vera Adradas, Santiago Ponce-Aix, Angel Nuñez-Buiza, Álvaro Ucero, Susana Hernandez, Fernando Lopez-Rios, Esther Conde, Luis Paz-Ares, Jon Zugazagoitia
BACKGROUND: Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small-cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and to identify biomarkers of long-term chemoimmunotherapy benefit in human ES-SCLC. PATIENTS AND METHODS: We analyzed tumor samples from 58 ES-SCLC patients enrolled in two multicenter single-arm phase IIIb studies evaluating front-line chemoimmunotherapy in Spain: n=32 from the IMfirst trial, and n=26 from the CANTABRICO trial...
April 17, 2024: Clinical Cancer Research
#2
JOURNAL ARTICLE
Alec Rhodes, Stephanie Moulton, Cäzilia Loibl, Donald Haurin, Joshua Joseph
OBJECTIVE: The medical diagnosis of a disease is common in older age and can carry significant financial costs. For many older adults, equity in a home is their primary component of wealth; however, housing wealth is illiquid. We analyze the relationship between the liquidation of housing wealth through mortgage borrowing on older homeowners' ability to successfully control a disease. METHODS: We use data on homeowners age 65 and older from the 1998-2016 waves of the Health and Retirement Study (N=3,457)...
April 17, 2024: Journals of Gerontology. Series B, Psychological Sciences and Social Sciences
#3
JOURNAL ARTICLE
Junqiu Liu, Zhaidong Liu, Chunqin Zhao, Yuting Jiao, Baohong Li, Jiaju Shi, Zichao Chen, Zhen Zhang
Exosomal programmed death ligand-1 (ExoPD-L1) is a vital marker of immune activation in the early stages of tumor therapy and it can inhibit anti-tumor immune responses. However, due to the low expression of ExoPD-L1 in cancer cells, it is difficult to perform highly sensitive assays and accurately differentiate cancer sources. Therefore, we constructed a coaxial dual-path electrochemical biosensor for highly accurate identification and detection of ExoPD-L1 from lung cancer based on chemical-biological coaxial nanomaterials and nucleic acid molecular signal amplification strategies...
April 17, 2024: Nanoscale
#4
JOURNAL ARTICLE
Qidong Cai, Mou Peng
BACKGROUND: Therapies targeting PD1/PD-L1 pathway have revolutionized the treatment of lung cancer. However, anti-PD1/PD-L1 therapies have proven beneficial for only a select group of lung adenocarcinoma (LUAD) patients and generally do not work for immuno-cold tumors characterized by a lack of immune cell infiltration. Identifying novel biomarkers is vital to broad therapeutic options for LUAD patients with no response to anti-PD1/PD-L1 immunotherapies. METHODS: Our study has developed a novel strategy to identify a promising biomarker that addresses the limitations of anti-PD1/PD-L1 immunotherapy in treating immunological cold tumors...
April 30, 2024: Heliyon
#5
JOURNAL ARTICLE
Xiaomiao Zhang, Xin Tong, Yuan Chen, Jun Chen, Yu Li, Cheng Ding, Sheng Ju, Yi Zhang, Hang Zhang, Jun Zhao
OBJECTIVE: This study aimed to identify differential metabolites and key metabolic pathways between lung adenocarcinoma (LUAD) tissues and normal lung (NL) tissues using metabolomics techniques, to discover potential biomarkers for the early diagnosis of lung cancer. MATERIAL AND METHODS: Forty-five patients with primary ground-glass nodules (GGN) identified on computed tomography imaging and who were willing to undergo surgery at Shanghai General Hospital from December 2021 to December 2022 were recruited to the study...
2024: CytoJournal
#6
JOURNAL ARTICLE
Zhenshan Zhao, Haiyang Li, Jing Li, Yao Rong, Lidong Zhao, Menghui Hao, Faming Tian
BACKGROUND: Molecular biology has been applied to the diagnosis, prognosis and treatment of various diseases, and long noncoding RNA LINC00943 (lncRNA LINC00943; LINC00943) plays an important role in a variety of cancers. Therefore, this study explored the prognostic role of LINC00943 in lung squamous cell carcinoma (LUSC) and understood its impact on the development of LUSC. METHODS: There are 89 LUSC patients were involved in current assay. By detecting the expression of LINC00943 and miR-196b-5p in tissues and cells, LINC00943 and its correlation with the characteristics of clinical data were analyzed...
April 16, 2024: Journal of Cardiothoracic Surgery
#7
JOURNAL ARTICLE
Yaji Li, Nan Wang, Yutang Huang, Shuai He, Meihua Bao, Chunjie Wen, Lanxiang Wu
Circular RNAs (circRNAs) play an important role in the development of acquired resistance to many anticancer drugs. We developed the Non-Small-Cell Lung Cancer (NSCLC) cell lines with acquired resistance to osimertinib, a third-generation of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), and evaluated the different expression profiles of circRNAs in osimertinib-sensitive and -resistant NSCLC cell lines using RNA sequencing (RNA-Seq). The expression of selected differentially expressed circRNAs was verified using quantitative real-time PCR (qRT-PCR) in paired osimertinib-sensitive and -resistant NSCLC cell lines, and in plasma samples of osimertinib-sensitive and -resistant NSCLC patients...
April 15, 2024: Cancer Genetics
#8
JOURNAL ARTICLE
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Nina Wyss, Fiamma Berner, Vincent Walter, Ann-Kristin Jochum, Mette T Purde, Marie-Therese Abdou, Tobias Sinnberg, Kathrin Hofmeister, Oltin T Pop, Omar Hasan Ali, Jens Bauer, Hung-Wei Cheng, Mechthild Lütge, Niklas Klümper, Stefan Diem, Zeynep Kosaloglu-Yalcin, Yizheng Zhang, Laura Sellmer, Boris Macek, Julia Karbach, David König, Heinz Läubli, Lars Zender, Britta S Meyer, Christoph Driessen, Christian M Schürch, Wolfram Jochum, Teresa Amaral, Lucie Heinzerling, Antonio Cozzio, Ahmed N Hegazy, Tino Schneider, Martin H Brutsche, Alessandro Sette, Tobias L Lenz, Juliane Walz, Hans-Georg Rammensee, Martin Früh, Elke Jäger, Burkhard Becher, Amanda Tufman, Nicolas Nuñez, Markus Joerger, Lukas Flatz
RATIONALE: Immune checkpoint inhibitor-related pneumonitis is a serious autoimmune event affecting up to 20% of patients with non-small cell lung cancer, yet the factors underpinning its development in some patients and not others are poorly understood. OBJECTIVES: To investigate the role of autoantibodies and autoreactive T cells against surfactant-related proteins in the development of pneumonitis. METHODS: The study cohort consisted of non-small cell lung cancer patients who gave blood samples before and during immune checkpoint inhibitor treatment...
April 16, 2024: American Journal of Respiratory and Critical Care Medicine
#9
JOURNAL ARTICLE
Kevin Tran, Daniel Ginzburg, Wei Hong, Ulrike Attenberger, Hyun Soo Ko
BACKGROUND: Lung cancer, the second most common cancer, presents persistently dismal prognoses. Radiomics, a promising field, aims to provide novel imaging biomarkers to improve outcomes. However, clinical translation faces reproducibility challenges, despite efforts to address them with quality scoring tools. OBJECTIVE: This study had two objectives: 1) identify radiomics biomarkers in post-radiotherapy stage III/IV nonsmall cell lung cancer (NSCLC) patients, 2) evaluate research quality using the CLEAR (CheckList_for_EvaluAtion_of_Radiomics_research), RQS (Radiomics_Quality_Score) frameworks, and formulate an amalgamated CLEAR-RQS tool to enhance scientific rigor...
April 16, 2024: European Radiology
#10
JOURNAL ARTICLE
Lynette M Sholl, Mark Awad, Upal Basu Roy, Mary Beth Beasley, Richard Walter Cartun, David M Hwang, Gregory Kalemkerian, Fernando Lopez-Rios, Mari Mino-Kenudson, Ajit Paintal, Kearin Reid, Lauren Ritterhouse, Lesley A Souter, Paul E Swanson, Christina B Ventura, Larissa V Furtado
CONTEXT.—: Rapid advancements in the understanding and manipulation of tumor-immune interactions have led to the approval of immune therapies for patients with non-small cell lung cancer. Certain immune checkpoint inhibitor therapies require the use of companion diagnostics, but methodologic variability has led to uncertainty around test selection and implementation in practice. OBJECTIVE.—: To develop evidence-based guideline recommendations for the testing of immunotherapy/immunomodulatory biomarkers, including programmed death ligand-1 (PD-L1) and tumor mutation burden (TMB), in patients with lung cancer...
April 16, 2024: Archives of Pathology & Laboratory Medicine
#11
JOURNAL ARTICLE
Huayan Ma, Yuxian Zhang, Jing Li, Tiantian Xie, Zhi Zhao
Osteosarcoma is a highly aggressive cancer prevalent among adolescents and young adults, notorious for its tendency to metastasize to the lungs. This research delves into the molecular foundations of osteosarcoma by examining the role of the Hippo signaling pathway and its interaction with the tumor immune microenvironment (TME). Through analysis of transcriptomic data from the TARGET-OS dataset and control samples from GTEx, we identified a set of 131 genes that link high expression profiles in osteosarcoma with the Hippo pathway...
April 15, 2024: Environmental Toxicology
#12
JOURNAL ARTICLE
Jia-Rong Wu, Vincent Chin-Hung Chen, Yu-Hung Fang, Ching-Chuan Hsieh, Shu-I Wu
OBJECTIVE: Anxiety is a prevalent comorbidity in lung cancer (LC) patients associated with a decline in quality of life. Dehydroepiandrosterone (DHEA), a neuroactive steroid, levels rise in response to stress. Prior research on the association between DHEA and anxiety has yielded contradictory results and no study has investigated this association in LC patients. METHODS: A total of 213 patients with LC were recruited from a general hospital. Data on demographic and cancer-related variables were collected...
April 15, 2024: BMC Cancer
#13
JOURNAL ARTICLE
Zhiyang Xu, Shaohang Wu, Jiahua Tu, Mingyang Wang, Weicheng Liang, Jiangdong Cheng, Jun Guan, Jianxin Xu
We aimed to investigate the expression and clinic significance of Rac GTPase Activating Protein 1 (RACGAP1) in human lung adenocarcinoma (LUAD). Online database analysis revealed a significant increase in RACGAP1 mRNA expression among 26 types of tumor tissues, including LUAD tissues. Online database and tissue microarray analyses indicated that RACGAP1 expression was significantly upregulated in LUAD tissues. Genetic variation analysis identified four different genetic variations of RACGAPs in LUAD. Moreover, online database analysis showed that RACGAP1 upregulation was correlated with shorter survival in patients with LUAD...
April 15, 2024: Scientific Reports
#14
REVIEW
Muhammad H Shahzad, Jonathan D Spicer, Valerie W Rusch, Peter J Kneuertz
Neoadjuvant immunotherapy has gone from an idea to an indication in locally advanced lung cancer. Several phase III trials have demonstrated the superiority of neoadjuvant chemoimmunotherapy compared to chemotherapy in this setting. Although such progress has revolutionized the treatment of locally advanced disease, the unmet needs of stage I and stage II patients without lymph node disease have largely been under-represented in existing trials. Up-front surgery with few patients going on to complete adjuvant therapy remains the norm for most stage I-II patients...
April 13, 2024: Annals of Thoracic Surgery
#15
JOURNAL ARTICLE
Yueh-Feng Lu, Ya-Hsuan Chang, Yi-Ju Chen, Min-Shu Hsieh, Mong-Wei Lin, Hsao-Hsun Hsu, Chia-Li Han, Yu-Ju Chen, Sung-Liang Yu, Jin-Shing Chen, Hsuan-Yu Chen
OBJECTIVES: With the increasing popularity of CT screening, more cases of early-stage lung cancer are being diagnosed. However, 24.5% of stage I non-small-cell lung cancer (NSCLC) patients still experience treatment failure post-surgery. Biomarkers to predict lung cancer patients at high risk of recurrence are needed. MATERIALS AND METHODS: We collected protein mass spectrometry data from the Taiwan Lung Cancer Moonshot Project and performed bioinformatics analysis on proteins with differential expressions between tumor and adjacent normal tissues in 74 stage I lung adenocarcinoma (LUAD) cases, aiming to explore the tumor microenvironment related prognostic biomarkers...
April 12, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
#16
JOURNAL ARTICLE
Lifang Wu, Xiang Chen, Tingting Peng, Enyan Tang, Wenjing Bai, Liya Chen
OBJECTIVES: This study aimed to assess the diagnostic value of human epididymal protein 4 (HE4), a potential novel biomarker for lung cancer, and its combined detection with five other conventional biomarkers in lung cancer diagnosis and subtyping. METHODS: In this retrospective study, 115 lung cancer patients, 50 patients with benign pulmonary disease, and 50 healthy controls were included. Serum HE4, progastrin-releasing peptide (ProGRP), squamous cell carcinoma (SCC) antigen, cytokeratin-19 fragment (CYFRA21-1), neuron-specific enolase (NSE), and carcinoembryonic antigen (CEA) were analyzed using the electrochemiluminescence immunoassay and chemiluminescence immunoassay...
April 15, 2024: International Journal of Biological Markers
#17
JOURNAL ARTICLE
Ling Yi, Ziwei Xu, Tianyu Ma, Chong Wang, Panjian Wei, Bo Xiao, Hongtao Zhang, Nanying Che, Zhidong Liu, Yi Han
PURPOSE: Neoadjuvant PD-1 blockade combined with chemotherapy is a promising treatment for resectable non-small cell lung cancer (NSCLC), yet the immunological mechanisms contributing to tumor regression and biomarkers corresponding to different pathological responses remain unclear. METHODS: Using dynamic and paired blood samples from NSCLC patients receiving neoadjuvant chemoimmunotherapy, we analyzed the frequencies of CD8 + T-cell and Treg subsets and their dynamic changes during neoadjuvant treatment through flow cytometry...
April 15, 2024: Cancer Immunology, Immunotherapy: CII
#18
JOURNAL ARTICLE
Bahareh Vakili, Parisa Shoaei, Kiana Shahzamani, Seyed Davar Siadat, Hasan Shojaei, Zahra Esfandiari, Elahe Nasri, Shiva Shabani, Ali Zamani Moghadam, Behrooz Ataei
BACKGROUND: Non-small cell lung cancer (NSCLC) patients with COVID-19 have an excessive chance of morbidity and mortality. The fecal-nasopharyngeal microbiota compositions of NSCLC patients were assessed in this study. METHODS: In total, 234 samples were collected from 17 NSCLC patients infected with COVID-19, 20 NSCLC patients without confirmed COVID-19, 40 non NSCLC patients with COVID-19, and 40 healthy individuals. RESULTS: In lung microbiota, the abundance of Streptococcus spp...
February 1, 2024: Archives of Iranian Medicine
#19
REVIEW
Sheyda Khalilian, Zahra Mohajer, Soudeh Ghafouri-Fard
Coagulation factor VIII (FVIII) is an essential cofactor in the coagulation cascade, encoded by the F8 gene on the long arm of chromosome X (Xq28). FVIII is normally circulated in complex with Von Willebrand factor (VWF) and has relevant emerging extracoagulative functions. Dysregulation of FVIII is associated with tumor progression, and could be used as a novel biomarker for tumor screening and monitoring. In breast cancer, bladder cancer, colorectal carcinoma, esophageal carcinoma, hepatocellular carcinoma and lung cancer, F8 is regarded as an oncogene...
2024: Avicenna Journal of Medical Biotechnology
#20
JOURNAL ARTICLE
Xiaoya Xu, Xiangru Shi, Dingjie Zhou, Dedong Cao
OBJECTIVE: This study aimed to assess the clinical value of the modified albumin-bilirubin (mALBI) grade in predicting the survival of patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy. METHODS: We conducted a retrospective cohort study of patients with advanced NSCLC who received immune checkpoint inhibitors (ICIs) from January 2020 to May 2022. The primary endpoints were overall survival (OS), treatment response, and the association between different mALBI grades and survival...
March 2024: Curēus
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
